XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Related Income Tax Benefit Stock-based compensation expense by statement of operations caption and the related income tax benefit were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Cost of sales$32 $38 $94 $117 
Research and development expenses283 326 817 1,004 
Selling, general and administrative expenses:
Employees
1,726 1,842 5,398 5,421 
Outside directors
94 233 524 1,033 
Total employee and director stock-based compensation expense$2,135 $2,439 $6,833 $7,575 
Income tax benefit$326 $397 $1,073 $1,265 
Stock Option Activity
Stock option activity was as follows:    
Number of Options
(in thousands)
Weighted-Average Exercise PriceWeighted-Average Remaining Contractual Term
(in years)
Aggregate Intrinsic Value
(in thousands)
Outstanding at December 31, 2022
782 $44.16 
Granted236 24.77 
Exercised— — $— 
Forfeited/canceled/expired(93)51.39 
Outstanding at September 30, 2023 (1)
925 $38.49 3.98$— 
Vested and expected to vest at September 30, 2023 (1)
925 $38.49 3.98$— 
Exercisable at September 30, 2023 (1)
604 $44.06 2.80$— 
(1)The aggregate intrinsic value represents the total pre-tax value (the difference between our closing stock price on the last trading day of the third quarter of 2023 and the exercise price, multiplied by the number of in-the-money options)
that would have been received by the option holders had they all exercised their options on September 30, 2023. This amount will change based on the fair market value of our stock.
Assumptions Used in Valuation and Weighted Average Fair Value of Stock Option Grants
The assumptions we utilized in the Black-Scholes option pricing model and the resulting weighted average fair value of stock option grants were the following:
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Weighted average fair value of grants$— $12.38 $10.83 $14.51 
Risk-free interest rate— %2.82 %3.86 %1.93 %
Expected volatility— %48.92 %45.89 %49.35 %
Expected life in years0.005.194.704.73
Non-Vested Restricted Stock Award Activity
Non-vested restricted stock award activity was as follows:
Shares
(in thousands)
Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2022
376 $36.82 
Granted340 14.15 
Vested(196)36.86 
Forfeited(4)38.19 
Non-vested at September 30, 2023
516 $21.83